Ipilimumab: A novel immunomodulating therapy causing autoimmune hypophysitis: A case report and review
Ipilimumab (Yervoy; Medarex and Bristol-Myers Squibb) is a human MAB against cytotoxic T-lymphocyte antigen 4, which enhances co-stimulation of cytotoxic T-lymphocytes, resulting in their proliferation and an anti-tumour response. It is licensed for the treatment of unresectable or metastatic malign...
Main Authors: | Juszczak, A, Gupta, A, Karavitaki, N, Middleton, MR, Grossman, AB |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2012
|
Similar Items
-
Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
by: Juszczak, A, et al.
Published: (2012) -
Ipilimumab-Induced Autoimmune Hypophysitis: Diagnostic and Management Challenges Illustrated by a Clinical Case
by: Pedro Marques, et al.
Published: (2015-10-01) -
Ipilimumab (Immune Checkpoint Inhibitors) Hypophysitis
by: Margot Stagnetto, et al.
Published: (2020-11-01) -
Ipilimumab cystic hypophysitis mimicking metastatic melanoma
by: John Wallace, BS, et al.
Published: (2018-06-01) -
Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report
by: Aoi Motonaga, et al.
Published: (2021-09-01)